




The Schnitzler syndrome is a rare and underdiagnosed entity which is considered today as being a paradigm of an
acquired/late onset auto-inflammatory disease. It associates a chronic urticarial skin rash, corresponding from the
clinico-pathological viewpoint to a neutrophilic urticarial dermatosis, a monoclonal IgM component and at least
2 of the following signs: fever, joint and/or bone pain, enlarged lymph nodes, spleen and/or liver, increased ESR,
increased neutrophil count, abnormal bone imaging findings. It is a chronic disease with only one known case of
spontaneous remission. Except of the severe alteration of quality of life related mainly to the rash, fever and pain,
complications include severe inflammatory anemia and AA amyloidosis. About 20% of patients will develop a lym-
phoproliferative disorder, mainly Waldenström disease and lymphoma, a percentage close to other patients with
IgM MGUS. It was exceedingly difficult to treat patients with this syndrome until the IL-1 receptor antagonist ana-
kinra became available. Anakinra allows a complete control of all signs within hours after the first injection, but
patients need continuous treatment with daily injections.
In many aspects, the Schnitzler syndrome resembles the genetically determined auto-inflammatory syndromes
involving activating mutations of the NLRP3 inflammasome. This latter point and its consequences will be
addressed.
Background
The Schnitzler syndrome is a rare and acquired systemic
disease which bears in common many features with a
group of inherited diseases referred to as auto-
inflammatory syndromes. Its main clinical features
include fever, an urticarial rash, muscle, bone and/or
joint pain and enlarged lymph nodes. A monoclonal
IgM component is the biological hallmark of the disease.
Conventional therapies including anti-histamines for the
skin rash, as well as anti-inflammatory drugs, steroids
and immunosuppressive drugs for the systemic signs,
are usually ineffective. However, the IL-1 receptor
antagonist anakinra was found to rapidly control all the
symptoms of this syndrome. However, signs recur as
soon as the treatment is stopped. About 15% to 20% of
patients with a Schnitzler’s will develop a lymphoproli-
ferative disorder, a prevalence shared with other patients
with monoclonal IgM gammopathies of undetermined
significance (MGUS) [1]. AA-amyloidosis is a concern
in untreated patients [2,3].
This review will provide a comprehensive overview of
the clinical and biological features of this syndrome,
emphasizing its particular rash, and summarize our cur-
rent comprehension of its pathophysiology, its complica-
tions and its treatment.
History
The different signs of this syndrome were first reported
in 1972 and then published in 1974 as an autonomous
entity by Liliane Schnitzler, a French dermatologist [4,5].
In the following years, cases were reported from all over
the world including North America and Japan, but
mostly from Europe. The European preeminence is
probably related to a better knowledge of this entity in
the old World. In 1999, Lipsker et al reported 4 cases
and performed an extensive literature review which
allowed them to establish diagnostic criteria [6], which
are currently accepted [3]. In their paper, they included
the CINCA (Chronic infantile Neurological Cutaneous
and Articular syndrome)/NOMID (Neonatal Onset
Multi-Inflammatory Disease) and the Muckle-Wells syn-
drome in the differential diagnosis and thus pointed for
the first time to similarities between the Schnitzler syn-
drome and the auto-inflammatory syndromes, of which
the latter are a paradigm. Indeed, the CINCA syndrome,
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the Muckle-Wells syndrome and familial cold auto-
inflammatory syndrome are different phenotypes of the
cryopyrinopathies, monogenic diseases involving the
innate immune system. Their pathophysiology implies
exaggerate activation of the inflammasome, an IL-1
synthesizing cellular machinery [7]. And indeed, IL-1
inhibition is a very effective treatment modality in
patients with CINCA. Since the Schnitzler syndrome
shares many features with the CINCA syndrome, ana-
kinra, an IL-1 inhibitor was also tried in the former syn-
drome. It proved to be the first really efficient treatment
of the Schnitzler syndrome.
Clinical Findings
The Schnitzler syndrome is characterized by a recurrent
febrile rash, joint and/or bone pain, enlarged lymph
nodes, fatigue, a monoclonal IgM component, leucocy-
tosis and systemic inflammatory response. The reviews
performed by Lipsker et al in 1999 and de Koning et al
in 2007 summarize most published cases [3,6]. They
form the basis of this review, to which the author’s own
experience with more than 10 patients, as well as recent
publications, is added. Diagnosis can be established
when the criteria summarized in Table 1 are met.
Epidemiology
There is a slight male predominance and mean age of
disease onset is 51 years. The youngest patient reported
started urticaria at age of 13, but the Schnitzler syn-
drome is basically a disease of the adult, since only four
patients started disease before age of 35 [3]. The delay
to diagnosis exceeds 5 years in many cases.
The skin rash
As the skin rash - with the monoclonal component - is
a defining criteria of the syndrome, it is present by defi-
nition in all patients. Patients with all signs of the
Schnitzler syndrome except the skin rash should be
referred to as Schnitzler-like syndrome [8].
The skin rash is usually the first clinical sign and most
patients started their disease with the eruption. The skin
rash was classically referred to as “urticaria”. However,
recently this peculiar rash was described in detail and
nosologically delineated from common urticaria [9].
Patients with the Schnitzler syndrome have a rose pale
or red eruption consisting of macules (flat lesions) or
slightly raised papules and plaques (Figure 1). They last
less than 24 hours, and are usually not or only moder-
ately itchy. Lesions can occur on every body part,
though involvement of face and extremities is rare. Ede-
matous swelling of the face (angioedema) is very rare
[3,10,11] and significant mucosal swelling with dyspnea
and/or dysphonia is exceptional. Many patients report
exacerbating factors including heat exposure, cold-expo-
sure, alcohol consumption, some aliments, physical
work, stress,... There is no specific chronology of the
rash, as would be typical for example in patients with
adult onset Still disease (AOSD) who report flares in the
late afternoon. Confluence of lesions is possible, as is
dermographism, i.e. friction of skin induces slightly
raised plaques, though they are usually not itchy as they
would be in authentic dermographism. The frequency of
flares is variable from patient to patient, and in the
same patient from factors we yet ignore. Patients can
have daily flares for months or years or remission for
days to weeks. It is however exceedingly rare to be free
of rash for a period longer than a month in untreated
patients. Skin lesions resolve within hours without any
sequel.
The histopathological findings are noteworthy [9,12].
When a typical plaque is biopsied at a relatively early
stage, a neutrophilic infiltrate of the dermis can be
found (Figure 2). The density of the infiltrate is variable.
Interstitial dispersion with neutrophils along the col-
lagen bundles is typical, as is significant leukocytoclasia
(Figure 3). There are no vasculitis and no significant
dermal edema, which allows distinction from urticarial
vasculitis and the Sweet syndrome respectively. The epi-
dermis is usually normal; hypodermal involvement with
neutrophils in the septa can be found, as can clustering
of neutrophils around sweat ducts realizing a histo-
pathologic aspect of eccrine hidradenitis as an epipheno-
menon. Vasculitis has been reported in up to 20% of
patients [3]. However, this author had the occasion to
review 4 biopsies of patients with the Schnitzler
Table 1 Diagnostic criteria of the Schnitzler syndrome
Urticarial skin rash1,2 and monoclonal IgM component3 and at





Liver or spleen enlargement
Elevated ESR
Leukocytosis
Abnormal findings on bone morphologic investigations
Another cause must be eliminated in all cases (see differential diagnosis),
most notably hyper IgD syndrome, adult onset Still disease, urticarial
hypocomplementemic vasculitis, acquired C1 inhibitor deficiency and
cryoglobulinemia.
1: the urticarial skin rash has now been extensively described and corresponds
nosologically to a neutrophilic urticarial dermatosis [9]
2: some authors have reported patients with all signs of the Schnitzler but
without the typical skin rash [8]; though those patients have probably a very
similar disease, until further characterization, the peculiar skin rash should
remain an obligate diagnostic criteria.
3: Some patients have a monoclonal IgG component instead of a monoclonal
IgM [reviewed in [3]]
4: In patients treated with IL-1 inhibitors, a rapid and immediate response is
supportive of the diagnosis. In case of unresponsiveness to anakinra, the
diagnosis should be reconsidered.
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syndrome previously interpreted as vasculitis, but in
which clear-cut signs of vasculitis were lacking and
which were re-interpreted as neutrophilic urticarial der-
matosis. Furthermore, though published photographies
of skin biopsies are rare, their careful examination rarely
shows authentic vasculitis. For example, the picture
published by Tanneberger et al and interpreted as vas-
culitis lack the typical features of the latter, as there is
no fibrinoid necrosis of vessel wall [13].
When immunofluorescence studies were performed,
deposition of immunoreactants, mainly IgM, could be
found around the superficial dermal vessels in about
30% of the patients [6,14-18]. In a few interesting obser-
vations, IgM deposits were found along the dermal-epi-
dermal junction [19-21]. It was demonstrated by means
of immunoelectron microscopic studies and immuno-
blotting on epidermal and dermal skin extracts, that
IgM-skin interactions occur [22]. Indeed, anti-skin IgM
autoantibodies of the same isotype as their monoclonal
gammopathies can be present in the serum of some
patients with the Schnitzler syndrome. These IgM auto-
antibodies seem to deposit in vivo in the epidermis and
at the dermal-epidermal junction, in the region of the
anchoring fibrils. Their exact significance remains
unclear, though it was postulated that they could trigger
a local inflammatory response that could induce the
skin lesions [22].
This rash, urticarial clinically, and a neutrophilic der-
matosis histopathologically was recently delineated
under the designation neutrophilic urticarial dermatosis
(NUD) [9]. NUD can also occur in patients with AOSD,
lupus erythematosus and cryopyrinopathies, which
should be considered in the differential diagnosis of the
Schnitzler syndrome [9].
The fever
Almost all patients will develop fever. The fever is inter-
mittent. Body temperature can rise above 40°C. Most
patients manage the fever and due its recurrent nature,
get used to it. The fever is usually well tolerated and
chills are rare. Fatigue is however frequent during the
fever flares. In most patients, there is no relation
between the fever and the skin rash. Fever responds in
some patients to NSAI drugs and/or to steroids and is
usually completely controlled with anakinra [6,23].
Musculoskelettal involvement
Musculoskelettal involvement is another cardinal feature
of the disease affecting about 80% of patients. Bone pain
is the most characteristic finding, but arthralgias and
sometimes fully developed arthritis, can occur. Joint
destruction and/or deformities have not been reported
so far. Bone pain affects mostly the iliac bone and the
tibia. Femur, spine, forearm and clavicle were less often
involved [24]. Bone involvement is common, and 30 to
40% of the patients showed bone lesions on imaging
Figure 1 the typical rash of the Schnitzler syndrome, which
corresponds to a neutrophilic urticarial dermatosis: rose to red
macules and/or slightly raised plaques. The lesions are usually
not itchy and vanish within hours without sequel.
Figure 2 (HE, × 200): a neutrophilic infiltrate of the dermis
without vasculitis and without significant edema.
Figure 3 (HE, × 200): significant neutrophilic infiltrate (arrow,
thin) with interstitial dispersion and leukocytoclasia (arrow,
thick).
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studies [25]. Osteocondensation is the most frequent
radiological finding and the most common radiological
pattern is a sclerotic bone marrow involvement with
cortical hyperostosis of distal femora and proximal
tibiae, and a lack of suggestive signs of malignancy.
Lytic lesions were reported [26,27] as well as periosteal
apposition [24,28]. Radiological differential diagnosis is
broad and includes mastocytosis, POEMS syndrome,
Erdheim-Chester disease, Camurati-Englemann or Van
Buchem disease, Buschke-Ollendorf syndrome, osteope-
trosis, melorheostosis, ribbing disease and hypertrophic
osteoarthropathy. Bone technetium scanning reveals
hyperfixation in the areas of radiological involvement
[24]. Magnetic resonance imaging confirms thickening
of cortices and can show medullar bone involvement
and marrow infiltration without space occupying fea-
tures in the affected areas [24,28,29]. A solitary sclerotic
lesion has been reported [30] and thus radiological
differential diagnosis should be expanded to include
entities as lymphoma, multiple myeloma, SAPHO syn-
drome, osteoblastic metastases, osteosarcoma, chronic
osteomyelitis, osteoid osteoma, and healing stress frac-
tures [31]. Bone biopsy of involved areas can be normal
[32,33] or show an unspecific inflammation in 5 patients
[34-38], sometimes associated with hyperactive osteo-
blasts. One patient had histological evidence of osteo-
sclerosis [21]. Heterotopic ossification after total hip
arthroplasty has been reported [39].
Organomegaly
Palpable lymph nodes are found in about 45% of the
patients and hepatic or splenic enlargement occurs in
about a third of the patients [3,6]. Palpable lymph nodes
are found in the axilla and inguinal sites and sometimes
in the cervical region. Those lymph nodes can be multi-
ple, permanent and up to 2 or 3 cm large and therefore




The monoclonal IgM component is a defining feature of
the syndrome and thus present in all patients [6].
Patients with all signs of the Schnitzler syndrome except
the monoclonal component should be referred to as
Schnitzler-like syndrome.
In more than 90% of patients, the monoclonal IgM
gammopathy is associated to a kappa light chain.
Usually, when diagnosis of the syndrome is made, IgM
levels are low (< 10 g/L in 67% of the patients). IgM
levels can remain stable or progressively increase at a
rate of about 0.5 to 1 g/L/year. High IgM levels should
raise suspicion of Waldenströms disease. When patients
are seen at the very beginning of the disease, monoclo-
nal IgM component can be present at very low (trace)
level (Lipsker, personnal observation). There are some
reports of Schnitzler syndromes (< 10% of reported
cases) with an associated IgG monoclonal component
[6,40] and even one report of a 58-year-old woman dis-
playing many clinical features of the syndrome and a
polyclonal increase in IgG and IgA [41]. Bence-Jones
proteinuria was reported in about 30% of the patients.
In about 25% of the patients, lowered levels of IgG or
IgA can be found [6]. At time of diagnosis, examination
of bone marrow is normal in 80% of the patients. In the
remaining 20%, unspecific, polyclonal, lymphocytic or
plasmocytic infiltrates were reported.
Other biological findings
During the course of the disease, elevated ESR is a con-
stant feature. Complement levels are normal or increased
in patients with this syndrome. When complement
levels are lowered, another diagnosis must be consid-
ered, especially hypocomplementic urticarial vasculitis
and cryoglobulinemia, and the possibility of a genetic
deficiency of C4 should be addressed, since 2 patients
with Schnitzler syndrome had a C4a deficiency [42]. An
inflammatory anemia, and sometimes thrombocytosis, is
present in up to 50% of the patients. Inflammatory ane-
mia can be very severe and symptomatic [6,15]. Persis-
tent leukocytosis of neutrophils (> 10 × 109/L), in the
absence of any treatment, occurs in more than 2/3 of
the patients [3,6]. This is a relevant finding in this clini-
cal context, as most auto-immune differential diagnoses
(urticarial vasculitis, cryoglobulinemia) are not asso-
ciated with increased number of neutrophils. In this
regard, both, adult onset Still’s disease and the Schnit-
zler syndrome can associate a skin rash, fever, palpable
lymph nodes, spleen and liver enlargement, arthralgias
and leukocytosis [43]. However, ferritine levels are
usually more elevated in the former while a monoclonal
IgM component is present in the latter.
Associated Findings
Associated findings include pseudoxanthum elasticum in
2 patients [44,45], peripheral neuropathy with the
presence of monoclonal IgM with anti-MAG (myelin-
associated glycoprotein) in 1 patient [46], C4 deficiency
in 2 patients [42] and nodular regenerative hyperplasia of
the liver in 1 patient [47], impairment of renal function
in 1 patient [48], thrombophilia with anti-phospholipid
antibodies and hyperhomocysteinemia [49] and hearing
loss [3]. This latter finding is especially interesting as it is
also found in the genetic auto-inflammatory diseases
Muckle-Wells and CINCA syndromes. The fact that
hearing loss resolved with anakinra further supports
strong similarities between the Schnitzler syndrome and
the latter group of diseases. This author is aware of
another patient with a monoclonal IgM component and
late-onset symptoms of Schnitzler syndrome and hearing
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loss, with a rash triggered by cold-exposure (Prof. J.-H.
Saurat, personal communication).
Disease Course and Complications
The course of the disease is longstanding. Spontaneous
or treatment-induced remissions have not been pub-
lished. At least 3 patients developed inflammatory AA
amyloidosis [2,3], a serious complication. However,
though patients have a longstanding course with a
monoclonal IgM component, no patient with systemic
AL amyloidosis has yet been reported. Nevertheless, AL-
amyloidosis should be considered as a possible compli-
cation of the syndrome.
The overall prognosis of the Schnitzler syndrome
depends on the possible evolution into a lymphoproli-
ferative disorder, either lymphoma, including lympho-
plasmacytic lymphoma, lymphoma of the Richter type,
marginal zone lymphoma, IgM myeloma or Walden-
ström’s disease [42,50-56]. About nineteen percent of
the reported patients with this syndrome developed lym-
phoproliferative disorders [3,6], a percentage close to the
18% prevalence at 10 years of lymphoproliferative disor-
ders in patients with IgM MGUS in general [1]. How-
ever, the number of patients with the syndrome who
will eventually develop lymphoproliferative disorder
could be higher, since most patients were published
shortly after diagnosis and therefore follow-up was too
short to draw any conclusion about long-term outcome.
Lymphoma or Waldenström’s disease appears more
than 10 to 20 years after the beginning of the first signs
of the syndrome in most cases. Schnitzler’s original
patient died from diffuse lymphoplasmacytic infiltration
of the liver and bone marrow 23 years after the begin-
ning of the disease [50]. In rare cases, Waldenström’s
disease was revealed by a Schnitzler syndrome [17].
There is no specific predictive factor of the development
of a lymphoproliferative disorder. Thus, initial work-up
of a patient with this syndrome should include an exam-
ination of bone marrow, immunoelectrophoresis of seric
and urinary proteins, and dosage of immunoglobulin
subtypes. The two latter examinations can then be used
to follow-up those patients on a biannual basis. Lymph
nodes should be biopsied when they enlarge.
This author is aware of one patient with a typical
Schnitzler syndrome which evolved for more than
8 years and then went into remission, without medical
treatment at this time [patient 2 in reference [6]]. The
remission now lasts for more than 5 years. The patient
has only exceptional cold- or stress- triggered crisis
once or twice a year. The monoclonal component is still
present at more than 30 g/L. To the best of this author’s
knowledge, this is the only patient who went into spon-
taneous remission.
Differential Diagnosis and Diagnostic Criteria
Diagnostic criteria are shown in Table 1. There is no
specific biological marker for this disease. Thus, diagno-
sis relies on a combination of clinical, biological and
radiological findings as well as on exclusion of another
cause. Especially, the following diseases/entities need to
be excluded: cryoglobulinemia, hypocomplementic urti-
carial vasculitis, acquired C1 inhibitor deficiency, hyper
IgD syndrome and adult onset Still’s disease. Further-
more, a spectacular and immediate response to anakinra
is another finding that supports the diagnosis, as already
suggested by Gilson et al. [57].
Pathophysiology
The pathophysiology of the fever and of the syndrome
in general remains unclear. Previous studies showed dis-
turbed cytokine balance. The presence of anti-IL-1 anti-
bodies was reported with increased frequency in this
syndrome by Saurat et al [58], but this finding was sub-
sequently not confirmed by other investigators
[18,21,36,59]. We found elevated IL-6 and/or IL-2
receptor levels in some patients and normal TNFa and
IL-8 levels (6). Although IL-6 is an essential plasma cell
growth factor, it is also an acute phase reactant and its
increase during a systemic illness is therefore not sur-
prising. Previous studies suggested that IgM deposits in
the skin seem to be involved in the pathophysiology of
the rash [22].
The main unresolved question is whether the clonal
IgM proliferation is primitive in nature or the result of a
continuous antigenic stimulation. Thus, the question
whether the Schnitzler syndrome is a smoldering lym-
phoproliferative disorder with systemic expression, com-
parable to the POEMS syndrome, or a systemic disorder
with an accompanying mIgM remains open. In rare
instances, treatment of the underlying lymphoprolifera-
tive disorder had a beneficial effect on the Schnitzler
syndrome, supporting the former point of view [60].
However, the Schnitzler syndrome shares many fea-
tures with genetically determined auto-inflammatory
syndromes:
- The recurrent fever of unknown cause;
- The peculiar eruption, characterized pathologically
by a neutrophilic infiltrate very similar to the one
observed in the auto-inflammatory cryopyrinopathies
(CINCA/NOMID syndrome, Muckle-Wells syn-
drome and familial cold-urticaria), namely a neutro-
philc urticarial dermatosis [9];
- A significant increase of neutrophils in blood and
tissues, not otherwise explained;
- An increased IL-1beta production by LPS-stimu-
lated peripheral blood monocytes [61,62];
Lipsker Orphanet Journal of Rare Diseases 2010, 5:38
http://www.ojrd.com/content/5/1/38
Page 5 of 8
- Elevated free circulating IL-18 levels, a cytokine
produced by the inflammasome [63];
- A genetic predisposition involving an activating
NLRP3 mutation, the gene involved in the cryopyri-
nopathies, which was demonstrated in one patient
[64];
- A spectacular response to the IL-1 inhibitor ana-
kinra [23,65], within hours after the first injection,
just as the one observed in the cryopyrinopathies,
suggesting a direct pathogenic effect of IL-1.
Thus, the Schnitzler syndrome is probably an
acquired auto-inflammatory syndrome. The monoclo-
nal IgM component could then either be the conse-
quence of a specific cytokinic activation pathway or it
could be directly involved in the pathogenesis via a
particular biological activity, as for example an agonist
activity on one of the IL-1 receptors or by fixing IL-1
and lowering its clearance without altering its biologi-
cal activity or by inhibiting the natural occurring IL-1
antagonist. This hypothesis is currently tested in an
international clinical study http://clinicaltrials.gov/ct2/
show/NCT00933296. If the latter hypothesis is con-
firmed, the Schnitzler syndrome would be an extrinsic
inflammasopathy.
Treatment
Many treatments used in the Schnitzler syndrome are
summarized in Table 2. Among the numerous drugs,
including anti-inflammatory and immunosuppressive
drugs, which have been tried, none could induce remis-
sion for a long time of all symptoms [reviewed in [6]].
Peflacine, a quinolone antibiotic could induce almost
complete remission in some patients, though its
mechanism of action remains largely unknown [66,67].
Thus, the Schnitzler syndrome was a very difficult-to-
treat syndrome and patients had to learn how to deal
on a daily basis with symptoms that could not be cor-
rectly relieved. This was changed with the use of the IL-
1 receptor antagonist anakinra. The first short note
about its efficiency was published by Martinez-Taboada
et al in 2005 [68] and it was subsequently confirmed by
many reports and this experience is shared by many
physicians treating patients with a Schnitzler syndrome
[23,57,64,69,70]. Anakinra, an IL-1 receptor antagonist
relieves all symptoms within hours after the first injec-
tion. Patients recover a health-state that they did not
know for years. Anakinra has a short half-live of about
6 hours and daily injections are necessary. In this
author’s experience, if a patient omits an injection,
symptoms, most notably fever, pain and the skin rash,
usually recur between the 35th and the 45th hour after
the last injection. A few patients seem to be relatively
well controlled with an injection every other day (J.-P.
Fermand, personal communication). Anakinra proved to
be the first efficient drug to treat this syndrome. We do
not yet have experience with other IL-1-blocking agents
as IL-1 trap or canakinumab. The main side-effects and
the contra-indications of anakinra are summarized in
the Additional file 1: table S1. Injection-site reactions
are frequent and sometimes severe, and can be a real
concern. The neutrophil count needs to be monitored.
As of today, it is the only treatment which showed regu-
lar efficiency in this syndrome.
Table 2 Treatments of patients with the Schnitzler syndrome before the use of anakinra
Treatment Comment
Steroids Suspensive, but usually requiring a high daily dosis (>40 mg equivalent of
prednisolone) to achieve improvement
Non steroid anti-inflammatory drugs, most notably ibuprofen Transient amelioration of fever and pain
Immunosuppressive drugs, including methotrexate,
azathioprine, cyclophosphamide
Usually ineffective
Colchicine, dapsone Transient improvement
Thalidomide Anecdotic reports of efficiency
TNF-blocking agents Ineffective
Immunoabsorption Only a single report
Intravenous immunoglobulins Ineffective
Rituximab Ineffective
Anti-histamines Usually ineffective, even on the skin rash
Phototherapy Transient amelioration of skin rash
Peflacine Efficient in some patients; recurrence if treatment is stopped.
Anakinra Complete and sustained remission of all symptoms; recurrence if treatment is
stopped
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Conclusion
This author considers that the Schnitzler syndrome is
the paradigm of a late-onset acquired auto-inflammatory
syndrome [71]. Though the term “auto-inflammatory
disease” is as yet restricted to diseases with mendelian
inheritance, the Schnitzler syndrome obviously shares
many clinical, biological and therapeutical aspects with
this group of diseases. Though there is no definite proof
of its precise pathogenesis, it should therefore be con-
sidered as an acquired disease involving abnormal sti-
mulation of the innate immune system, which can be
completely reversed by the IL-1 receptor antagonist ana-
kinra. It clearly expands our view of this group of rare
genetic diseases and makes the concept of auto-inflam-
mation relevant to polygenic acquired diseases.
Additional material
Additional file 1: Table S1. Main side-effects and contra-indications of
anakinra.
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